12:40 PM EDT, 10/07/2024 (MT Newswires) -- Liquidia ( LQDA ) shares climbed more than 14% in recent Monday trading after the US Supreme Court denied a request by United Therapeutics ( UTHR ) for a review of previous rulings over a patent infringement dispute between the two companies.

The high court's rejection of United Therapeutic's petition means that the US Court of Appeals for the Federal Circuit's 2023 ruling affirming the decision of Patent Trial and Appeal Board in 2022 against United Therapeutics' ( UTHR ) patent claims is "final and not subject to further appeal," Liquidia ( LQDA ) said

The board had ruled against United Therapeutics' ( UTHR ) patent covering claims related to Liquidia's ( LQDA ) Yutrepia, or treprostinil, inhalation powder to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Liquidia ( LQDA ) said the US Food and Drug Administration's final approval for Yutrepia may occur after the three-year regulatory exclusivity for United Therapeutics' ( UTHR ) Tyvaso DPI for the treatment of similar ailment expires on May 23 next year.

United Therapeutics ( UTHR ) did not immediately reply to MT Newswires' request for comment. Its shares were down about 1%.

Price: 11.51, Change: +1.48, Percent Change: +14.71